Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation

Neuroscience

Volumn 266, Issue , 2014, Pages 255-265

  Noh, H ^a   Seo, H ^a  

^a Hanyang University   (South Korea)

Author keywords

AD; Aging; Cognitive improvement; NGF; SAPP; VPA

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CHOLINE ACETYLTRANSFERASE; HISTONE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; NERVE GROWTH FACTOR; PROTEIN TYROSINE KINASE A; TAU PROTEIN; TOLL LIKE RECEPTOR 4; VALPROIC ACID; ENZYME INHIBITOR;

AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CHOLINERGIC NERVE CELL; COGNITION; CONTROLLED STUDY; DISEASE COURSE; ENZYME INHIBITION; ESCAPE BEHAVIOR; HIPPOCAMPUS; HISTONE MODIFICATION; IN VIVO STUDY; LATENT PERIOD; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SPATIAL MEMORY; AGING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; MAZE TEST; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

AGING; ALZHEIMER DISEASE; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MAZE LEARNING; MICE; MICE, TRANSGENIC; NERVE GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VALPROIC ACID;

EID: 84896262392     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.02.012     Document Type: Article

References (55)

1. Abel T., Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 2008, 8:57-64.
2. Arriagada P.V., Marzloff K., Hyman B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42:1681-1688.
3. Ascolani A., Balestrieri E., Minutolo A., Mosti S., Spalletta G., Bramanti P., Mastino A., Caltagirone C., Macchi B. Dysregulated NF-kappaB pathway in peripheral mononuclear cells of Alzheimer's disease patients. Curr Alzheimer Res 2012, 9:128-137.
4. Blanco A., Alvarez S., Fresno M., Munoz-Fernandez M.A. Amyloid-beta induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-kappa B dependent manner. J Alzheimers Dis 2010, 22:493-505.
5. Calissano P., Matrone C., Amadoro G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease. Dev Neurobiol 2010, 70:372-383.
6. Cao P., Liang Y., Gao X., Zhao M.G., Liang G.B. Administration of MS-275 improves cognitive performance and reduces cell death following traumatic brain injury in rats. CNS Neurosci Ther 2013, 19:337-345.
7. Capsoni S., Brandi R., Arisi I., D'Onofrio M., Cattaneo A. A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model. CNS Neurol Disord Drug Targets 2011, 10:635-647.
8. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009, 32:591-601.
9. Crutcher K.A., Scott S.A., Liang S., Everson W.V., Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci 1993, 13:2540-2550.
10. Cuadrado-Tejedor M., Ricobaraza A.L., Torrijo R., Franco R., Garcia-Osta A. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer s disease-like phenotype of a commonly used mouse model. Curr Pharm Des 2013, 19:5076-5084.
11. D'Onofrio M., Arisi I., Brandi R., Di Mambro A., Felsani A., Capsoni S., Cattaneo A. Early inflammation and immune response mRNAs in the brain of AD11 anti-NGF mice. Neurobiol Aging 2011, 32:1007-1022.
12. Dowdell K.C., Pesnicak L., Hoffmann V., Steadman K., Remaley A.T., Cohen J.I., Straus S.E., Rao V.K. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr-/- murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 2009, 37:487-494.
13. Fahnestock M., Scott S.A., Jette N., Weingartner J.A., Crutcher K.A. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Brain Res Mol Brain Res 1996, 42:175-178.
14. Fischer A., Sananbenesi F., Wang X., Dobbin M., Tsai L.H. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447:178-182.
15. Francis Y.I., Fa M., Ashraf H., Zhang H., Staniszewski A., Latchman D.S., Arancio O. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 2009, 18:131-139.
16. Ginsberg S.D., Che S., Wuu J., Counts S.E., Mufson E.J. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 2006, 97:475-487.
17. Govindarajan N., Agis-Balboa R.C., Walter J., Sananbenesi F., Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 2011, 26:187-197.
18. Govindarajan N., Rao P., Burkhardt S., Sananbenesi F., Schluter O.M., Bradke F., Lu J., Fischer A. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med 2013, 5:52-63.
19. Graff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J., Fass D.M., Kao P.F., Kahn M., Su S.C., Samiei A., Joseph N., Haggarty S.J., Delalle I., Tsai L.H. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
20. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., LaFerla F.M. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008, 28:11500-11510.
21. Guedes-Dias P., Oliveira J.M. Lysine deacetylases and mitochondrial dynamics in neurodegeneration. Biochim Biophys Acta 2013, 1832:1345-1359.
22. Hu J.P., Xie J.W., Wang C.Y., Wang T., Wang X., Wang S.L., Teng W.P., Wang Z.Y. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways. Brain Res Bull 2011, 85:194-200.
23. Jimenez S., Torres M., Vizuete M., Sanchez-Varo R., Sanchez-Mejias E., Trujillo-Estrada L., Carmona-Cuenca I., Caballero C., Ruano D., Gutierrez A., Vitorica J. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J Biol Chem 2011, 286:18414-18425.
24. Jin J.J., Kim H.D., Maxwell J.A., Li L., Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflamm 2008, 5:23.
25. Johnson A.A., Sarthi J., Pirooznia S.K., Reube W., Elefant F. Increasing Tip60 HAT levels rescues axonal transport defects and associated behavioral phenotypes in a Drosophila Alzheimer's disease model. J Neurosci 2013, 33:7535-7547.
26. Karagiannis T.C., Ververis K. Potential of chromatin modifying compounds for the treatment of Alzheimer's disease. Pathobiol Aging Age Relat Dis 2012, 2:14980-14987.
27. Kilgore M., Miller C.A., Fass D.M., Hennig K.M., Haggarty S.J., Sweatt J.D., Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35:870-880.
28. Kim D., Tsai L.-H. Bridging physiology and pathology in AD. Cell 2009, 137:997-1000.
29. Konsoula Z., Barile F.A. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J Pharmacol Toxicol Methods 2012, 66:215-220.
30. Kozikowski A.P., Chen Y., Subhasish T., Lewin N.E., Blumberg P.M., Zhong Z., D'Annibale M.A., Wang W.L., Shen Y., Langley B. Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. ChemMedChem 2009, 4:1095-1105.
31. Lalonde R., Fukuchi K., Strazielle C. APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). Neurosci Biobehav Rev 2012, 36:1357-1375.
32. Manaye K.F., Mouton P.R., Xu G., Drew A., Lei D.L., Sharma Y., Rebeck G.W., Turner S. Age-related loss of noradrenergic neurons in the brains of triple transgenic mice. Age (Dordrecht, Netherlands) 2013, 35:139-147.
33. Manzo F., Tambaro F.P., Mai A., Altucci L. Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat 2009, 19:761-774.
34. Nalivaeva N.N., Belyaev N.D., Lewis D.I., Pickles A.R., Makova N.Z., Bagrova D.I., Dubrovskaya N.M., Plesneva S.A., Zhuravin I.A., Turner A.J. Effect of sodium valproate administration on brain neprilysin expression and memory in rats. J Mol Neurosci 2012, 46:569-577.
35. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Valproic acid stimulates clusterin expression in human astrocytes: implications for Alzheimer's disease. Neurosci Lett 2010, 475:64-68.
36. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006, 26:10129-10140.
37. Perez M., Santa-Maria I., Gomez de Barreda E., Zhu X., Cuadros R., Cabrero J.R., Sanchez-Madrid F., Dawson H.N., Vitek M.P., Perry G., Smith M.A., Avila J. Tau - an inhibitor of deacetylase HDAC6 function. J Neurochem 2009, 109:1756-1766.
38. Polydoro M., Acker C.M., Duff K., Castillo P.E., Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009, 29:10741-10749.
39. Qing H., He G., Ly P.T., Fox C.J., Staufenbiel M., Cai F., Zhang Z., Wei S., Sun X., Chen C.H., Zhou W., Wang K., Song W. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008, 205:2781-2789.
40. Rabe S., Reichwald J., Ammaturo D., de Strooper B., Saftig P., Neumann U., Staufenbiel M. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing. J Neurochem 2011, 119:231-239.
41. Rao J.S., Keleshian V.L., Klein S., Rapoport S.I. Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients. Transl Psychiatry 2012, 2:e132.
42. Ricobaraza A., Cuadrado-Tejedor M., Marco S., Perez-Otano I., Garcia-Osta A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 2012, 22:1040-1050.
43. Ricobaraza A., Cuadrado-Tejedor M., Perez-Mediavilla A., Frechilla D., Del Rio J., Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-1732.
44. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439.
45. Scott S.A., Mufson E.J., Weingartner J.A., Skau K.A., Crutcher K.A. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995, 15:6213-6221.
46. Seo H., Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp Neurol 2005, 193:469-480.
47. Song M., Jin J., Lim J.E., Kou J., Pattanayak A., Rehman J.A., Kim H.D., Tahara K., Lalonde R., Fukuchi K. TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflamm 2011, 8:92.
48. Sung Y.M., Lee T., Yoon H., DiBattista A.M., Song J.M., Sohn Y., Moffat E.I., Turner R.S., Jung M., Kim J., Hoe H.S. Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp Neurol 2013, 239:192-201.
49. Udan M.L., Ajit D., Crouse N.R., Nichols M.R. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem 2008, 104:524-533.
50. Vadnal J., Houston S., Bhatta S., Freeman E., McDonough J. Transcriptional signatures mediated by acetylation overlap with early-stage Alzheimer's disease. Exp Brain Res 2012, 221:287-297.
51. Venero J.L., Knusel B., Beck K.D., Hefti F. Expression of neurotrophin and trk receptor genes in adult rats with fimbria transections: effect of intraventricular nerve growth factor and brain-derived neurotrophic factor administration. Neuroscience 1994, 59:797-815.
52. Venkataramani V., Rossner C., Iffland L., Schweyer S., Tamboli I.Y., Walter J., Wirths O., Bayer T.A. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem 2010, 285:10678-10689.
53. Zhang W., Wang L.Z., Yu J.T., Chi Z.F., Tan L. Increased expressions of TLR2 and TLR4 on peripheral blood mononuclear cells from patients with Alzheimer's disease. J Neurol Sci 2012, 315:67-71.
54. Zhang X., Luhrs K.J., Ryff K.A., Malik W.T., Driscoll M.J., Culver B. Suppression of nuclear factor kappa B ameliorates astrogliosis but not amyloid burden in APPswe/PS1dE9 mice. Neuroscience 2009, 161:53-58.
55. Zhang Z.Y., Schluesener H.J. Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J Neuropathol Exp Neurol 2013, 72:178-185.